NZ731396B2 - Compositions and methods for the treatment of multiple sclerosis - Google Patents
Compositions and methods for the treatment of multiple sclerosis Download PDFInfo
- Publication number
- NZ731396B2 NZ731396B2 NZ731396A NZ73139614A NZ731396B2 NZ 731396 B2 NZ731396 B2 NZ 731396B2 NZ 731396 A NZ731396 A NZ 731396A NZ 73139614 A NZ73139614 A NZ 73139614A NZ 731396 B2 NZ731396 B2 NZ 731396B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compositions
- formula
- administration
- treatment
- compound
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract description 135
- 201000006417 multiple sclerosis Diseases 0.000 title abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 52
- 239000011780 sodium chloride Substances 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 230000000699 topical Effects 0.000 claims abstract description 10
- 206010053643 Neurodegenerative disease Diseases 0.000 claims abstract description 7
- 239000007924 injection Substances 0.000 claims abstract description 7
- 200000000018 inflammatory disease Diseases 0.000 claims abstract description 6
- 238000002347 injection Methods 0.000 claims abstract description 6
- 239000006188 syrup Substances 0.000 claims abstract description 6
- 235000020357 syrup Nutrition 0.000 claims abstract description 6
- 238000007911 parenteral administration Methods 0.000 claims abstract description 5
- 239000012453 solvate Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 34
- -1 hydrate Substances 0.000 claims description 17
- 230000003111 delayed Effects 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 7
- 230000002459 sustained Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 201000004681 psoriasis Diseases 0.000 claims description 3
- 229940100688 Oral Solution Drugs 0.000 claims description 2
- 230000000626 neurodegenerative Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 abstract description 6
- 150000004677 hydrates Chemical class 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 description 34
- 229940079593 drugs Drugs 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 239000002552 dosage form Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 21
- 239000000463 material Substances 0.000 description 19
- 239000003826 tablet Substances 0.000 description 19
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 16
- 239000000969 carrier Substances 0.000 description 13
- 230000001225 therapeutic Effects 0.000 description 12
- 239000010410 layer Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 239000001993 wax Substances 0.000 description 9
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 8
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 210000001519 tissues Anatomy 0.000 description 8
- 230000001070 adhesive Effects 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 239000000945 filler Substances 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 210000000056 organs Anatomy 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 235000010419 agar Nutrition 0.000 description 6
- 235000010443 alginic acid Nutrition 0.000 description 6
- 229920000615 alginic acid Polymers 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 230000002829 reduced Effects 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 241000416162 Astragalus gummifer Species 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 241000229754 Iva xanthiifolia Species 0.000 description 5
- 229920001615 Tragacanth Polymers 0.000 description 5
- 229940116362 Tragacanth Drugs 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrugs Drugs 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000010487 tragacanth Nutrition 0.000 description 5
- 239000000196 tragacanth Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 210000001124 Body Fluids Anatomy 0.000 description 4
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 4
- 210000002381 Plasma Anatomy 0.000 description 4
- 229920001283 Polyalkylene terephthalate Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 235000012216 bentonite Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008079 hexane Substances 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 3
- 210000003169 Central Nervous System Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 3
- 230000001058 adult Effects 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 125000004429 atoms Chemical group 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 210000004027 cells Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229920000591 gum Polymers 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003902 lesions Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000002503 metabolic Effects 0.000 description 3
- 230000000926 neurological Effects 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 235000021251 pulses Nutrition 0.000 description 3
- 239000011342 resin composition Substances 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000002522 swelling Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- OMDQUFIYNPYJFM-XKDAHURESA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[[(2R,3S,4R,5S,6R)-4,5,6-trihydroxy-3-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 description 2
- 229960005069 Calcium Drugs 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 2
- 229940113118 Carrageenan Drugs 0.000 description 2
- 229920002301 Cellulose acetate Polymers 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- DJHJJVWPFGHIPH-OODMECLYSA-N Chitin Chemical compound O[C@@H]1C(NC(=O)C)[C@H](O)OC(CO)[C@H]1COC[C@H]1C(NC(C)=O)[C@@H](O)[C@H](COC[C@H]2C([C@@H](O)[C@H](O)C(CO)O2)NC(C)=O)C(CO)O1 DJHJJVWPFGHIPH-OODMECLYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 230000037242 Cmax Effects 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 230000036081 Excretion rate Effects 0.000 description 2
- 229920000926 Galactomannan Polymers 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- 230000035809 INACTIVATION RATE Effects 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N Inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 Inulin Drugs 0.000 description 2
- 229920001543 Laminarin Polymers 0.000 description 2
- 239000005717 Laminarin Substances 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 229920002521 Macromolecule Polymers 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 230000035888 Maximum plasma concentration Effects 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 101710036039 NOTCH4 Proteins 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 229940067631 Phospholipids Drugs 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001225 Polyester resin Polymers 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 2
- 229940032147 Starch Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 241000388430 Tara Species 0.000 description 2
- 230000036201 Tissue concentration Effects 0.000 description 2
- 230000035507 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 150000003868 ammonium compounds Chemical class 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 230000002209 hydrophobic Effects 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000266 injurious Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 2
- 238000001690 micro-dialysis Methods 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 230000003278 mimic Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 230000002093 peripheral Effects 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 239000004645 polyester resin Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000000241 respiratory Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000001187 sodium carbonate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- PUSNGFYSTWMJSK-GSZQVNRLSA-N (2R,3R,4S,5R,6R)-2,3,4-trimethoxy-6-(methoxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[(2R,3R,4S,5R,6S)-3,4,5-tris(2-hydroxypropoxy)-6-[(2R,3R,4S,5R,6R)-4,5,6-tris(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)oxan- Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](OC)O[C@@H]1COC.CC(O)CO[C@@H]1[C@@H](OCC(C)O)[C@H](OCC(C)O)[C@@H](COCC(O)C)O[C@H]1O[C@H]1[C@H](OCC(C)O)[C@@H](OCC(C)O)[C@H](OCC(C)O)O[C@@H]1COCC(C)O PUSNGFYSTWMJSK-GSZQVNRLSA-N 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N 1,2,3-propanetrioltrinitrate Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- DCBSHORRWZKAKO-UHFFFAOYSA-N 1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- 229960000583 Acetic Acid Drugs 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 229940043253 Butylated Hydroxyanisole Drugs 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N C[N+](C)(C)CCO Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 229940073532 Candelilla Wax Drugs 0.000 description 1
- 229940063834 Carboxymethylcellulose Sodium Drugs 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229940039227 DIAGNOSTIC AGENTS Drugs 0.000 description 1
- 208000004275 Demyelinating Disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 229960001484 Edetic Acid Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N Glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N Hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 201000001971 Huntington's disease Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 101710004181 INTS2 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 229960000448 Lactic acid Drugs 0.000 description 1
- 230000035832 Lag time Effects 0.000 description 1
- 230000035648 Lag-time Effects 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 210000002751 Lymph Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 210000000274 Microglia Anatomy 0.000 description 1
- 210000003470 Mitochondria Anatomy 0.000 description 1
- 229920000460 Mitochondrial DNA Polymers 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 210000003097 Mucus Anatomy 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010052639 Nerve injury Diseases 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 229960002715 Nicotine Drugs 0.000 description 1
- 229940074730 OPHTHAMOLOGIC DIAGNOSTIC AGENTS Drugs 0.000 description 1
- 241000875883 Phytopythium vexans Species 0.000 description 1
- 229940069328 Povidone Drugs 0.000 description 1
- 206010056486 Pre-existing disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940100618 Rectal Suppository Drugs 0.000 description 1
- 206010038428 Renal disease Diseases 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- FEBUJFMRSBAMES-UHFFFAOYSA-N Scleroglucan Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
- 239000004783 Serene Substances 0.000 description 1
- 241000527181 Sisor Species 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 239000004163 Spermaceti wax Substances 0.000 description 1
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Stearin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N Talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 240000000280 Theobroma cacao Species 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 101700028444 USO1 Proteins 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 101700061199 WNT1 Proteins 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N Xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2R,3S,4R,5R,6S)-6-[[(1R,3S,4R,5R,8S)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1R,3R,4R,5R,8S)-8-[(2S,3R,4R,5R,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000003008 brain-resident macrophage Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000024881 catalytic activity Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 201000008779 central nervous system disease Diseases 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000002706 dry binder Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-M ethyl carbonate Chemical compound CCOC([O-])=O CQDGTJPVBWZJAZ-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003492 excitotoxic Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 201000002406 genetic disease Diseases 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940074050 glyceryl myristate Drugs 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
- 235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 230000003451 hyperinsulinaemic Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 231100000896 loss of balance Toxicity 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 125000004492 methyl ester group Chemical group 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 230000002438 mitochondrial Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- 229930015196 nicotine Natural products 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000399 orthopedic Effects 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 230000001846 repelling Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000012176 shellac wax Substances 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019385 spermaceti wax Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/593—Dicarboxylic acid esters having only one carbon-to-carbon double bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/593—Dicarboxylic acid esters having only one carbon-to-carbon double bond
- C07C69/60—Maleic acid esters; Fumaric acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Abstract
The invention relates to the compounds of formula II or their pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of compounds of formula II and methods for treating or preventing multiple sclerosis. The compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous or parenteral administration, as a syrup, or for injection. Such compositions may be used in the treatment of neurodegenerative diseases and other inflammatory diseases. methods for treating or preventing multiple sclerosis. The compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous or parenteral administration, as a syrup, or for injection. Such compositions may be used in the treatment of neurodegenerative diseases and other inflammatory diseases.
Description
(12) Granted patent specificaon (19) NZ (11) 731396 (13) B2
(47) Publicaon date: 2021.12.24
(54) COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
(51) Internaonal Patent Classificaon(s):
C07C 69/60 C07C 271/16 A61K 31/232 A61K 31/27 A61P 25/00
(22) Filing date: (73) Owner(s):
2014.11.20 CELLIX BIO E LIMITED
(23) Complete specificaon filing date: (74) t:
2014.11.20 Griffith Hack
(30) Internaonal Priority Data: (72) Inventor(s):
IN 4873/CHE/2014 2014.09.29 KANDULA, Mahesh
(86) Internaonal Applicaon No.:
(87) Internaonal Publicaon number:
WO/2016/051420
(57) Abstract:
The invenon relates to the nds of formula II or their pharmaceucal acceptable salts, as
well as polymorphs, solvates, enanomers, stereoisomers and hydrates thereof. The invenon
further s to pharmaceucal composions comprising an effecve amount of compounds
of formula II and methods for treang or prevenng e sclerosis. The ions may be
formulated for oral, buccal, rectal, topical, ermal, transmucosal, intravenous or parenteral
administraon, as a syrup, or for injecon. Such composions may be used in the treatment of
neurodegenerave diseases and other inflammatory diseases.
NZ 731396 B2
2014/000726
COMPOSITIONS AND METHODS FOR THE
TREATMENT OF MULTIPLE SCLEROSIS
PRIORITY
The present application claims the benefit of Indian Provisional Patent
Application No. 4873/CHE/2014 filed on 292014, the entire disclosure of which is
relied on for all purposes and is incorporated into this application by reference.
FIELD OF THE INVENTION
This disclosure generally relates to compounds and compositions for the treatment
of multiple sclerosis. More particularly, this invention relates to ng subjects with a
aceutically acceptable dose of compounds, stereoisomers, enantiomers, crystals,
esters, salts, hydrates, prodrugs, or mixtures thereof.
BACKGROUND OF THE INVENTION
Multiple sclerosis (MS) is an atory, autoimmune, demyelinating disease
of the central nervous system. It generally strikes at an early age, most often the early
adult years. Its most freQuent symptoms include numbness, impaired vision, loss of
balance, weakness, bladder dysfunction, and psychological changes. Fatigue is an early
symptom in MS, often the earliest. The disease can wax and wane for up to 30 years, but
in perhaps half of all cases it ly progreSSes to severe disability and premature death.
MS is the most common cause of neurologic disability in young adults. The
lesions of demyelination are histopathologically characteristic of the disease. Brain
examination by MRI tic resonance imaging) can ely detect these “white
matter plaques.” MRI correlates well with the classic histopathology of the lesions, and is
progressively a more sensitive tool for detecting the teristic lesiOns of MS in situ,
as compared to conventional functional evaluation. Multiple sclerosis is a x
disease, perhaps assing more than a single etiopathological entity and very likely
subject to actorial etiology. MS prevalenceworldwide is estimated at one million
cases; in the United States this number is 250,000—350,000. Although not generally
considered life threatening, this disease kills about 3,000 people each year in the United
The etiology of neurodegenerative diseases remains enigmatic; however, evidence
for defects in energy metabolism,‘excitotoxicity, and for ive damage is increasingly
compelling. It is likely that there is a complex interplay, between these mechanisms.
Mitochondria are the major intracellular source of ‘free radicals, and increased
mitochondrial calcium concentrations enhance free radical tion. 'Mitochondrial
DNA is particularly susceptible to ive stress, and there is evidence of age-
dependent damage and deterioration of respiratory enzyme activities withnormal aging.
This may contribute to the delayed onset and age ence of neurodegenerative
diseases. There is evidence for increased oxidative damage to macromolecules in
ophic lateral sclerosis, Multiple sis, Huntington’s disease, Parkinson’s.
disease, and Alzheimer’s disease.
[0006‘] Inflammation is a self-defensive reaction aimed at eliminating or neutralizing '
injurious i, and restoring tissue integrity.»~ In neurodegenerative diseases '
inflammation occurs as a local response driven by microglia, in the e of leukocyte
infiltration. Like peripheral inflammation, neuroinflammation‘ may become a harmful
process, and it is now widely accepted that it may contribute to the pathogenesis of many
central nervous system disorders, ineluding chronic neurodegenerative diseases such as
Multiple sis.
Managing acute pathology of often relies on the addressing underlying pathology
and symptoms of the disease. There is currently a need in the art for new compositions to
treatment or delay of the onset of multiple sclerosis and its associated complications
ssion.
SUMMARY OF THE INVENTION
[0008) The present invention provides compounds, compositions containing these
compounds and methods for using the same to treat, prevent and/or ameliorate the
effects of the conditions such as multiple sclerosis.
[0008A] In one aspect there is provided a compound of Formula II:
Formula II
or a ceutically acceptable salt, e, solvate, enantiomer, or stereoisomer thereof;
R1, R3 are each independently null:
R2 is
; and
R4 represents
17897439_1 (GHMatters) P109613.NZ
[0008B] In another aspect there is provided a pharmaceutical composition comprising a
compound as defined herein and a pharmaceutically acceptable carrier.
[0008C] In another aspect there is provided use of a compound as defined herein for the
manufacture of a medicament for the treatment of egenerative diseases, le
sclerosis, psoriasis and inflammatory diseases.
[0009) The invention herein provides itions comprising of formula I or
pharmaceutical acceptable salts thereof. The invention also provides pharmaceutical
compositions comprising one or more compounds of a I or intermediates thereof
and one or more of ceutically acceptable carriers, vehicles or diluents. These
compositions may be used in the treatment of multiple sclerosisand its associated
complications.
Formula I
(0010] In n embodiments, the present invention relates to the compounds and
compositions of formula I, or pharmaceutically able salts thereof,
3a followed by Page 4
17897439_1 (GHMatters) P109613.NZ
2014/000726
Formula I
Wherein,
Rl R3each independently represents —CH3CO-, acetyl, D, H, CD3CO-,
0is, Rome/z:OH
2;:\/\S/\/“\;
or flown/[Lg
R2, R4each independently represents H, D,
WO 51420
WO 51420
2014/000726
NHCOCH3
o o
C65“ (1‘32“ CONH
“‘5‘ 2
0;; ’
OH o OCOCH3 0&7.
’ ’
‘55f CH3
CH 0
CH3 6"
OH 77 o
A °
HN NH HO
H H
u H2N OH
a is independently 2,3 or 7;
each b is independently. 3, 5 or 6;
e is independently 1, 2 or 6;
c and d are each independently H, D, -OH, -OD, C1-C6-alkyl, -NH2 or —COCH3.
The invention herein also provides compositions comprising of a II or
pharmaceutical acceptable salts f. The invention also provides pharmaceutical
compositions comprising one or more compounds of formula II or intermediates thereof
and one or more of pharmaceutically'acceptable carriers; vehicles or ts. These
compositions may be used in the treatment of multiple sclerosis and its associated
V complications.
ANXM
Formula II
Accordingly, in certain embodiments, the present invention relates to the
compounds and cOmpositions of formula II, or phannaceutically able salts thereof,
0/ \R4
Formula II
Wherein
Rl R3each independently represents H, D,
'0' o
,\O:4"
WO 51420
R2, R4 each ndently represents D, CH3CO, CD3CO,
2014/000726
0 o O
H3C/ \n/\/U\O/ HO O
O a
/3: .
O 15:
HO 0H 0
, ,
2014/000726
NHCOCH3
WO 51420
”N ' NH HO
a is independently 2,3 or 7;
each b is independently 3, 5 or 6;
e is independently 1, 2 or 6;
c and d are each independently H, D, -OH, -OD, C1-C6-alky1, -NH2 or ~COCH3.
In the rative embodiments, examples of compounds of formula I are as set
forth below:
O 0
o 0
/\=/\._./\=/\_—J\=W xfiJKONo/NM‘a H
(1-1)
‘ 0 o
o 0 -
._ _—
" __ “\L-N/fl\
H ‘\\
. o
O s
V \S
(1-2) .
In the rative embodiments, exemples of compounds of formula II are as set
forth below:
WO 51420
91 £1 01 L
61 '— ___f O
— "' _‘
—- O
0__\\—-N/u\
o MO\
H O
(2-1)
Herein the application also provides a kit comprising any of the pharmaceutical
compositions disclosed herein. The kit may'comprise instructions for use in the treatment
of le sisor its related complications.
The application also discloses a pharmaceutical composition comprising a
pharmaceutically able carrier and any of the compositions herein. In some aspects,
the pharmaceutical composition is formulated for systemic administration, oral
administration, sustained release, parenteral stration, injection, subdermal
administration, or transdermal administration.
Herein, the application additionally es kits comprising the pharmaceutical
compositions described herein The kits may further comprise instructions for use in the
treatment of multiple sclerosisor its related complications.
The compositions described herein have several uses. The present application
provides, for example, methods of treating a t sufiering from multiple sclerosisor
its related complications manifested from neurodegeneration, neurological dysfunction,
lic conditions or disorders, metabolic syndrome, chronic diseases or disorders;
Hyperinsulinemia, Insulin ance, Glucose intolerance, Hepatology, Cancer,
Respiratory, Hematological, Orthopedic, Cardiovascular, Renal, Skin, Nephrological, or
Ocular complications.
BRIEF DESCRIPTION OF FIGURES:
Example embodiments are illustrated by way of example and not limitation in the figures
of theaccompanying drawings, in which like references indicate similar elements and in
which:
. 1 shows the 1H —NMR results for Formula 11.
FIGURE. 2 shows the 13C —NMR s for Formula II.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
As used herein, the following terms and phrases shall have the meanings set forth
below. Unless defined otherwise, all technical and scientific terms used herein have the
same g as commonly understood to one of ordinary skill in the art.
The compounds. of the present invention can be present in the form of
pharmaceutically acceptable salts. The compounds of the present invention can also be
present in the form of pharmaceutically able esters (i.e., the methyl and ethyl esters
of the acids of formula I and a II to be used as gs). The compounds of the
t invention can also be solvated, i.e. hydrated. The l9dentate19 can be affected in
the course of the manufacturing process or can take place i.e. as a consequence of
hygroscopic properties of an initially anhydrous compound of formula I and formula II
(hydration).
Compounds that have the same molecular formula but differ in the nature or
sequence of bonding of their atoms or the arrangement of their atoms in space are termed
“isomers.” Isomers that differ in the arrangement of their atoms in space aretermed
“stereoisomers.” Diastereomers are stereoisomers with opposite configuration at one or
more chiral centers which are not omers. Stereoisomers bearing one or more
asymmetric centers that are non- superimposable mirror images of each other are termed
iomers.” When a compound has an asymmetric center, for example, if a carbon
atom is bonded to four different groups, a pair of enantiomers is possible. An enantiomer
can be characterized by the absolute ration of its asymmetric center or centers and
is described by the R— and S-sequencing rules iof Cahn, lngold and , or by the
manner in which the molecule rotates the plane of polarized light and ated as
dextrorotatory or levorotatory (i.e., as (+) or (-)—isomers respectively). A chiral compound
can exist as either individual enantiomer or as a mixture thereof. A mixture containing
equal proportions of the enantiomers is called a “racemic mixture”.
As used herein, the term “metabolic condition” refers to an Inbom errors of
metabolism (or genetic metabolic cOnditions) are genetic disorders that result from a
defect in one or more metabolic ys; specifically, the function Of an enzyme is
affected and is either deficient or completely absent.
The term “polymorph” as used herein is art-recognized and refers to one crystal
structure of a given nd.
The phrases teral administration” and “administered parenterally” as used
herein refer to modes of administration other than enteral and topical administration, such
as injections, and include without limitation‘intravenous, intramuscular, intrapleural,
intravascular, intrapericardial, intraarterial, intrathecal, intracapsular, intraorbital,
intracardiac, intradennal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-
‘ lar, subcapsular, subarachnoid, intraspinal and intrastemal injection and infilsion.
A “patient,” “subject,” or “host” to be treated by the subject method may mean
either a human or non-human animal, such as primates, mammals, and vertebrates.
The phrase aceutically acceptable” is art-recognized. In certain
ments, the term includes compositions, polymers and other materials and/or
dosage forms which are, within the scope of sound medical nt, suitable for use in
contact with the tissues of mammals, human beings and animals without excessive
toxicity, irritation, allergic response, or other problem or complication, commensurate
with a reasonable benefit/risk ratio.
The phrase f‘pharmaceutically able carrier” is art-recognized, and includes,
for example, ceutically acceptable materials, compositions or vehicles, such as a
liquid or solid filler, 21dentate, solvent or encapsulating material involved in carrying or
transporting any subject composition, from one organ, or portion of the body, to another
organ, or portion of the body. Each carrier must be “acceptable” in the sense of being
compatible with the other ingredients of a subject composition and not injurious to the
patient. In certain embodiments, a ceutically acceptable r is rogenic.
Some examples of materials which may serve as pharmaceutically acceptable carriers
include: ( 1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch
and potato starch; (3) ose, and its derivatives, such as sodium ymethyl
cellulose, ethyl ose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6)
gelatin; (7) tale; (8) cocoa butter and suppository waxes; (9) oils, such as peanut oil,
cottonseed oil, sunflower oil, sesame oil, oliVe oil, corn oil and soybean oil; (10) glycols,
such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and
polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate;-( 13) agar; (l4)
buffering agents, such as magnesium hydroxide and um hydroxide; (15) alginic
acid; (16) pyrogen-free water; (17) ic saline; (18) Ringer’s solution; (19) ethyl
alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances
employed in pharmaceutical formulations.
The term
ug” . is
ed to encompass nds that, under
physiologiCal conditions, are converted into the therapeutically active agents of the
present invention. A common method for making a prodrug is to include selected
moieties that are hydrolyzed under physiological ions to reveal the desired
7. molecule. In other embodiments, the prodrug is converted by an enzymatic activity of the
host animal.
The term “prophylactic or therapeutic” treatment is art-recognized and includes
administration to the host of one or more of the t compositions. If it is
administered prior to clinical manifestation of the ed condition (e.g., disease or
other unwanted state of the host animal) then the treatment is prophylactic, i.e., it protects
the host against developing the unwanted cOndition, whereas if it is administered afier
station of the unwanted condition, the treatment is therapeutic, (i.e., it is intended
to diminish, rate, or ize the exiSting unwanted condition or side effects
thereof).
The term “predicting” as used herein refers to assessing the probability related;
diseases patient will suffer from abnormalities or complication and/or terminal platelet
aggregation or failure and/or death (i.e. mortality) within a defined time window
(predictive window) in the future. The mortality may be caused by the central nervous
System or complication. The tive window is an interval in which the subject will
develop one or more of the said complications according to the predicted ility. The
predictive window may be the entireremaining lifespan of the subject upon analysis by
the method of the present invention.
The term “treating” is art —recognized and includes preventing a disease, disorder
or condition from occurring in an animal which may be predisposed to the disease,
disorder and/or condition but has not yet been diagnosed as having it; inhibiting the
disease, disorder or condition, e.g., impeding its progress; and relieving the disease,
er, or condition, e.g., causing regression of the disease, disorder and/or condition.
Treating the disease or condition includes ameliorating at least one symptom of the
particular e or condition, even if the underlying pathophysiology is not affected,
such as treating the neurological condition such as multiple sclerosis and other diseases
related to ive stress such as renal diseases of a t by administration ofan agent
even though such agent does not treat the cause of the condition. The term “treating”,
“treat” or ment” as Used herein es curative, preventative (e.g., prophylactic),
t and palliative treatment.
The phrase “therapeutically effective amount” is an art-recognized term. In
certain embodiments, the term refers to an amount of a salt or composition disclosed
herein that produces. some desired effect at a reasonable benefit/risk ratio applicable to
any medical treatment. In n embodiments, the term refers to that amount necessary
or sufficient to eliminate or reduce medical symptoms for a period of time. The effective
amount may vary depending on such factors as the disease or cendition being treated, the
particular targeted constructs being administered, the size of the subject, or the severity of
the disease or condition. One of ordinary skill in the art may empirically determine the
effective amount of a particular composition without itating undue
experimentation.
In certain embodiments, the pharmaceutical compositions described herein are
formulated in a manner such that said compositions will be delivered to a patient in a
eutically effective amount, as part‘of a prophylactic or therapeutic treatment. The
desired amount of the composition to be administered to a t will depend on
absorption, inactivation, and excretion rates of thedrug as well as the delivery rate of the
salts and compositions from the subject compositions. It is to be noted that dosage values
may also vary with the severity of the condition to be alleviated. It is to be further
understood that for any particular subject, specific dosage regimens should be adjusted
over time according to the individual need and the professional judgment of the person
administering or supervising the stration of the compositions. Typically, dosing
will be determined using techniques known to one skilled in the art.
Additionally, the optimal concentration and/or quantities or s of any
ular salt or composition may be ed to accommodate variations in the
. treatment parameters. Such treatment include the clinical use to which the
_ parameters
preparation is put, e.g., the site treated, the type of patient, e.g., human or non-human,
adult or child, and the nature of the disease or condition.
In certain embodiments, the dosage of the subject compositions provided herein
may be determined by reference to the plasma concentrations of the therapeutic
composition or other encapsulated materials. For examme, the maximum plasma
- concentration (Cmax) and the area under the plasma concentration-time curve from time
0 tr) infinity may be used.
[0038‘] When used with respect to a pharmaceutical composition or other material, the
term “sustained release” is art-recognized. For example, a subject composition which
releases a substance over time may exhibit sustained e characteristics, in contrast to
a bolus type administration in which the entire amount of the substance is made
biologically available at one time. For example, in particular embodiments, upon contact
with body fluids including blood, spinal fluid, mucus secretions, lymph or the like, one or
more of the pharmaceutically acceptable excipients may o gradual or delayed
ation '(e.g., through hydrolysis) with concomitant release of any material
incorporated therein, e.g., an therapeutic and/or biologically active salt and/or
composition, for a sustained or ed period (as compared to the release from a
bolus). This release may result in prolonged delivery of therapeutically effective
amounts of any of the therapeutic agents disclosed herein.
The phrases “systemic administration,7, 6‘administered systemically,39 6‘peripheral
administration” and “administered peripherally” are art-recognized, and include the
administration of a subject composition, therapeutic or other material at a site remote
from the disease being treated. Administration of an agent for the disease being treated,
even if the agent is subsequently distributed systemically, may be termed “local” or
“topical” or “regional” administration, other than directly into the central nervous system,
e.g., by subcutaneous administration, such that it enters the patient’s system and, thus, is
subject to lism and other like processes.
The phrase “therapeutically effective amount” is an art-recognized term. t In
certain embodiments, the term refers to an amount of a salt or composition disclosed
herein that produces some desired effect at a reasonable benefit/risk ratio applicable to
any medical treatment. In certain embodiments, the term refers to that amount necessary
Or sufficient to eliminate or reduce l symptoms for a period of time. The ive
amount may vary ing on such factors as the disease or condition being treated, the
particular ed constructs being administered, the size of the t, or the severity of
the disease or ionf One of ordinary skill in the art may cally determine the
effective amount of a particular composition without necessitating undue
mentation.
The present disclosure also contemplates prodrugs of the compositions disclosed
herein, as well as pharmaceutically acceptable salts of said prodrugs.
This application also discloses a pharmaceutical ition comprising a
pharmaceutically acceptable carrier and the composition of a compound of Formula I and
formula II may be formulated for systemic or topical or oral administration. The
pharmaceutical composition may be also ated for oral administration, oral solution,
injection, subdermal administration, or ermal administration. The pharmaceutical
composition may further se at least one of a pharmaceutically acceptable
stabilizer, 26dentate, surfactant, filler, binder, and lubricant.
In many embodiments, the pharmaceutical compositions described herein will
incorporate the disclosed compounds and compositions (Formula I and Formula II) to be
delivered in an amount sufficient to deliver to a t a therapeutically effective amount
of a compound of formula I and formula II or composition as part of a prophylactic or
therapeutic treatment. The desired concentration of formula I and a II or its
pharmaceutical acceptable salts will depend on absorption, inactivation, and excretion
rates of the drug as well as the delivery rate of the salts and compositions from the
t compositions. It is to be noted that dosage values may also vary with the ty
of the ion to be alleviated. It is to be further understood that for any particular
subject, specific dosage regimens should be adjusted over time according to the
individual need and the professional judgment of the person administering or ising
the administration of the compositions. Typically, dosing will be determined ’using
techniques known to one skilled in the art.
onally, the optimal concentration and/or quantities or amounts of any
particular compound Vof formula I and formula II may be adjusted to accommodate
variations in the treatment parameters. Such treatment parameters include the clinical use
to which the preparation is put, e.g., the site treated, the type of patient, e.g., human or
non-human, adult or child, and the nature of the disease or condition.
The concentration and/or amount of any nd of formula I and formula 11
may be readily identified by routine screening in animals, e.g., rats, by ing a range
of concentration and/or amounts of the material in question using appropriate assays.
Known methods are also available to assay local tissue concentrations, diffusion rates of
the salts or compositions, and local blood flow before and after administration of
therapeutic formulations disclosed herein. One such method is ialysis, as
reviewed by T. E. Robinson et al., 1991, microdialysis in the neurosciences, Techniques,
V ‘The
volume 7, Chapter 1. methods reviewed by Robinson may be applied, in brief, as
follows. A microdialysis loop is placed in situ in a test animal. Dialysis fluid is. pumped
through the loop. When compounds with formula I and formula II such as those
disclosed herein are injected adjacent to the loop, released drugs arecolleCted in the
dialysate in proportion to their local tissue concentrations. The progress of diffusion of
the salts or itions may be determined y .with le calibration procedures
using known concentrations of salts or compOsitions.
In certain embodiments, the dosage of the subject compounds Of formula I and
formula 11 ed herein may be determined by reference to the plasma concentrations
of the therapeutic .composition or other encapsulated materials. For example, the
maximum plasma concentration (Cmax) and the area under the plasma concentration-
time curve from time 0 to infinity may be used.
Generally, in ng out the s detailed in this application, an effective
dosage for the compounds of Formulas I is inthe range‘of about 0.01 day to about
100 day in single or divided doses, for instance 0.01 mg/kg/day to about 50
mg/kg/day in single or divided doses. The compounds of Fortnulas I may be administered
at a dose of, for e, less than 0.2 mg/kg/day, 0.5 mg/kg/day, 1.0 mg/kg/day, 5
mg/kg/day, 10 mg/kg/day, 20 mg/kg/day, 30 mg/kg/day, or 40 mg/kg/day. Compounds of
Formula I and formula 11 may also be administered to a human patient at a dose of, for
example, between 0.1 mg and 1000 mg, between 5 mg and 80 mg, or less than 1.0, 9.0,
12.0, 20.0, 50.0, 75.0, 100, 300, 400, 500, 800, 1000, 2000, 5000 mg per day. In certain
embodiments, the compositions herein are administered at an Mount that is less than
95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10% of the compound of formula
I and formula 11 required for the same therapeutic benefit.
An effective amount of the compounds of formula I and formula 11 described
herein refers to the amount of one of said salts or compositions which is capable of
inhibiting or preventing a disease.
An effective amount may be sufficient to prohibit, treat, alleviate, ameliorate, halt,
restrain, slow or reverse the progression, or reduce the severity of a cation
resulting from nerve damage or demyelization and/or elevated reactive ivenitrosative
species and/or abnormalities in neurotransmitter homeostasis’s, in patients
who are‘at risk for Such complications. As such, these methods include both medical
therapeutic (acute) and/or prophylactic (prevention) administration as appropriate. The
amount and timing of compositions stered will, of course, be dependent on the
subject being treated, on the severity of the affliction, on the manner of administration
and on the judgment of the prescribing physician. Thus, because of patient-to—patient
variability, the dosages given above are a ine and the ian may titrate doses of
the drug to achieve the treatment that the physician considers appropriate for the patient.
In ering the degree of treatment desired, the physician must e a y of
factors such as age of the patient, ce of preexisting disease, as well as presence of
other diseases.
The compositions provided by this application may be administered to a subject
in need of treatment by a variety of conventional routes of administration, ing
orally, topically, parenterally, e.g., intravenously, subcutaneously or intramedullary.
Further, the compositions may be administered intranasally, as a rectal suppository, or
using a “flash” formulation, i.e., allowing the medication to dissolve in the mouth t
the need to use water. Furthermore, the compositions may be administered to a subject in
need of treatment by controlled release dosage forms, site specific drug delivery,
transdermal drug delivery, patch (active/passive) mediated drug delivery, by stereotactic
ion, or in nanoparticles.
The compositions may be administered alone or in combination with
pharmaceutically acceptable carriers, vehicles or diluents, in either single or multiple
doses. Suitablepharmaceutical carriers, vehicles and diluents e inert solid diluents
or fillers, sterile aqueous solutions and various organic solvents. The pharmaceutical
compositions formed by combining the compositions and the pharmaceutically
. able carriers, vehicles or diluents are then readily stered in a variety of
dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like.
These pharmaceutical itions can, if desired, contain onal ingredients such as
flavorings, binders, excipients and the like. Thus, for purposes of oral administration,
tablets containing various excipients such as nine, sodium e, calcium
carbonate and calcium phosphate may be employed along with various egrates such
as starch, alginic acid and certain complex silicates, together with binding agents such as
polyvinylpyrrolidone, sucrose, n and . Additionally, lubricatingagents such
as magnesium stearate, sodium lauryl sulfate and talc are ofien useful for tabletting
purposes. Solid compositions of a similar type may also be employed as fillers in sofi and
hard filled gelatin capsules. Appropriate materials for this include lactose or milk sugar
and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are ‘
desired for oral administration, the essential active ingredient therein may be combined
with various sweetening or flavoring agents, ng matter or dyes and, if desired,
emulsifying or suspending agents, together with diluents such as water, ethanol,
propylene glycol, glycerin and combinations thereof. The compounds of formula I and
formula Il may also comprise enterically coated comprising of s excipients, as is
well known in the pharmaceutical art.
For parenteral administration, solutions of the compositions may be prepared in
(for example) sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous
solutions may be employed. Such s solutions should be suitably buffered if
necessary and the liquid 30 dentate first rendered isotonic with sufficient saline or
glucose. These particular aqueous solutions are especially le for intravenous,
intramuscular, subcutaneous and intraperitoneal administration. In this connection, the
sterile aqueous media employed are all readily available by standard techniques known to
those skilled in the art.
The formulations, for instance s, may contain e.g. 10 to 100, 50 to 250, 150
to 500 mg, or 350 to 800 mg e.g. 10, 50, 100, 300, 500, 700, 800 mg ofthe compounds of
formula I and formula II disclosed herein, for instance, nds of formula I and
formula II or pharmaceutical acceptable salts of a compounds of Formula I.
Generally, a composition as described herein may be administered orally, or
parenterally (e.g., enous, intramuscular, subcutaneous or intramedullary). Topical
administration may also be indicated, for example, where the patient is suffering frOm
gastrointestinal er that prevent oral administration, or whenever the medication is
best applied to the surface of a tissue or organ as determined by the attending physician.
Localized administration may also be indicated, for example, when a high dose is d
at the target tissue or organ. For buccal administration the active ition may take
the form of tablets or lozenges formulated in aconventional .
The dosage administered will be ent upon the identity of the neurological
disease; the type of host involved, including its age, health and weight; the kind of
concurrent treatment, if any; the frequency of treatment and therapeutic ratio.
Illustratively, dosage levels of the administered active ingredients are:
intravenous, 0.1 to about 200 mg/kg; intramuscular, 1 to about 500 mg/kg; orally, 5 to
about 1000 mg/kg; intranasal instillation, 5 to about 1000 mg/kg; and aerosol, 5 to about
1000 mg/kg of host body weight.
Expressed in terms of concentration, an active ingredient can be present in the
compositions of the present invention for localized use about the cutis, intranasally,
pharyngolaryngeally, bronchially, intravaginally, rectally, or ocularly in a tration
of from about 0.01 to about 50% w/‘w of the composition; preferably about 1- to about
% w/w ofthe composition; and for parenteral use in a concentration of from about 0.05
to about 50% w/v ofthe ition and preferably from about 5 to about 20% w/v. ,
The compositions of the present ion are preferably presented for
administration to humans and animalsin unit dosage forms, such as tablets, capsules,
pills, powders, es, suppositories, sterile parenteral solutions or sions, sterile
non-parenteral solutions of suspensions, and oral ons or suspensions and the like,
containing suitable quantities of an active ingredient. For oral administration either solid
or fluid unit dosage forms can be prepared.
. [0059] As discussed above, the tablet core contains one or more hilic polymers.
Suitable hilic polymers include, but are not limited to, water ble cellulose
derivatives, polyalkylene glycols, thermoplastic polyalkylene oxides, acrylic polymers,
olloids, clays, gelling starches, swelling cross—linked polymers, and mixtures
thereof. Examples of suitable water Swellable cellulose derivatives include, but are not
limited to, sodium carboxymethylcellulose, cross-linked hydroxypropleellulose,
hydroirypropyl cellulose (HPC), ypropylmethylcellulose (HPMC),
hydroxyisopropylcellulOse, ‘ hydroxybutylcellulose, hydroxyphenylcellulose,
hydroxyethylcellulose (HBO), hydroxypentylcellulose, hydroxypropylethylcellulose,
hydroxypropylbutylcellulose, and hydroxypropylethylcellulose, and mixtures thereof.
Examples of suitable polyalkylene s include, but are not limited to, polyethylene
glycol. Examples of suitable thermoplastic polyalkylene oxides e, but are, not
limited to, poly(ethylene oxide). Examples of suitable acrylic polymers include, but are
not limited to, potassium methacrylatedivinylbenzene copolymer,
polymethylmethacrylate, olecular weight crosslinked acrylic acid homopolymers
and copolymers such as those commercially available from Noveon Chemicals under the
tradename CARBOPOLTM. Examples of suitable olloids include, but are not
limited to, alginates, agar, guar gum, locust bean gum, kappa carrageenan, iota
carrageenan, tara, gum 32 denta, ' tragacanth, pectin, xanthan gum, gellan gum,
maltodextrin, galactomannan, pusstulan, laminarin, glucan, gum 32denta, inulin,
pectin, gelatin, 32denta, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan, and ~
mixtures f. Examples of le clays inelude, but are not limited to, smectites
such as bentonite, kaolin, and laponite; magnesium trisilicate; magnesium aluminum
silicate, and mixtures thereof. Examples of suitable gelling starches e, but are not
limited to, acid hydrolyzed es, swelling starches such as sodium starch glycolate
and derivatives thereof, and mixtures thereof. Examples of suitable swelling linked
polymers include, but are not limited to, cross-linked polyvinyl pyrrolidone, cross-linked
agar, and cross—linked carboxymethylcellulose sodium, and mixtures thereof.
The carrier may contain one or more suitable entsfor the formulation of
s. Examples of suitable excipients include, but are not limited to, fillers, adsorbents,
binders, disintegrants, lubricants, glidants, release-modifying excipients,
superdisintegrants, idants, and mixtures f.
Suitable binders include, but are not limited to, dry binders such as polyvinyl
pyrrolidone and hydroxypropylmethylcellulose; wet binders such as water-soluble
polymers, including olloids such as acacia, alginates, agar, guar gum, locust bean,
carrageenan, carboxymethylcellulose, tara, gum 32 denta, tragacanth, pectin, xanthan,
, gelatin, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, inulin,
33 denta, rhamsan, zooglan, methylan‘, chitin, cyclodextrin, chitosan, polyvinyl
pyrrolidone, cellulosics, sucrose, and starches; and mixtures f. Suitable
disintegrants include, but are not limited to, sodium starch glycolate, cross-linked
polyvinylpyrrolidone, cross-linked ymethylcellulose, starches, microcrystalline
cellulose, and mixtures thereof.
Suitable lubricants include, but are not limited to, long chain fatty acids and their
salts, such as magnesium te and stearic acid, talc, glycerides waxes, and mixtures
thereof. Suitable ts include, but are not limited to, colloidal silicon dioxide.
Suitable e-modifying excipients include, but are not limited to, insoluble edible
materials, Ph-dependent polymers, and mixtures thereof.
le insoluble edible materials for use as release-modifying excipients
include, but are not limited to, water~insoluble rs and low-melting hydrophobic
materials, copolymers thereof, and mixtures f. Examples of suitable water-
ble polymers include, but are not‘ limited to, ethylcellulose, nyl alcohols,
polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates,
methacrylates, acrylic acid copolymers, copolymers thereof, and mixtures thereof.
Suitable low-melting hydrophobic materials include, but are not limited to, fats, fatty acid
esters, phospholipids, waxes, and mixtures thereof. Examples of suitable fats include, but
are not limited to, hydrogenated vegetable oils such as for example cocoa butter,
hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated er oil,
and hydrogenated soybean oil, free fatty acids and their salts, and mixtures thereof.
Examples of suitable fatty acid esters include, but are not limited to, sucrose fatty acid
esters, mono-, di-, and triglycerides, ylbehenate, glycerylpalmitostearate,
glycerylmonostearate, glyceryltristearate, yltrilaurylate, glycerylmyristate,
GlycoWax—932, lauroyl macrogol-32 glycerides, stearoyl macrogol-32 ides, and
mixtures thereof. Examples of suitable phospholipids include phosphotidyl choline,
phosphotidyl serene, phosphotidylenositol, otidic acid, and mixtures thereof.
Examples of suitable waxes include, but are not limited to, a wax, spermaceti
wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and n wax; fat-
containing mixtures such as chocolate, and mixtures thereof. Examples of super
disintegrants include, but are not d to, croscarrnellose sodium, sodium starch
glycolate and cross-linked povidone ovidone). In one embodiment the tablet core
contains up to about 5 percent by weight of such super disintegrant.
Examples of antioxidants include, but are not limited to, erols, ascorbic
acid, sodium pyrosulfite, butylhydroxytoluene, butylated hydroxyanisole, edetic acid, and
ate salts, and mixtures thereof. Examples of preservatives include, but are not
limited to, citric acid, tartaric acid, lactic acid, malic acid, acetic acid, benzoic acid, and
sorbic acid, and mixtures thereof.
In one embodiment, the immediate release g has an average thickness of at
least 50 microns, such as fiom about 50 microns to about 2500 microns; e.g., from about ’
'250 s to about 1000 microns. In embodiment, the immediate release coating is
typically compressed at a density of more than about 0.9 g/cc, as measured by the weight
and volume ofthat specific layer.
In one embodiment, the immediate release g contains a first portion and a
second portion, wherein at least one of the portions contains the second pharmaceutically
active agent. In one embodiment, the portions contact each other at a center axis of the
tablet. In one embodiment, the first portion includes the first pharmaceutically active
agent and the second portion includes the second pharmaceutically active agent.
In one embodiment, the first n contains the first pharmaceutically active
agent and the second portion contains the second pharmaceutically active agent. In one
embodiment, one of the portions contains a third pharmaceutically active agent. In one
embodiment one Of the portions contains a second immediate release portion of the same
pharmaceutically active agent as that ned in the tablet core.
In one embodiment, the outer. coating portion is prepared as a dry blend of
materials prior to addition to the coated tablet core. In another embodiment the outer
coating portion is included of a driedgran‘ulation including the pharmaceutically active
agent.
Formulations with different drug release isms bed above could be
combined in a final dosage form containing single or multiple units. Examples of
multiple units include multilayer tablets, capsules containing tablets, beads, or granules in
'a solid or liquid form. Typical, immediate release formulations e compressed
s, gels, films, coatings, liquids and particles that can be encapsulated, for example,
in a gelatin e. Many methods for preparing gs, covering or incorporating
drugs, are known. in the art.
The immediate release dosage, unit of the dosage form, i.e., a tablet, a plurality of
drug-containing beads, es or particles, or an outer layer of a coated core dosage
form, contains‘a therapeutically ive quantity of the active agent with conventional
pharmaceutical excipients. The immediate release dosage unit may or may not be coated,
and may or may not be admixed with the delayed release dosage unit or units (as in an
encapsulated mixture of immediate release drug-containing granules, particles or beads
and delayed release drug—containing granules or beads).
Extended release formulations are generally prepared as diffusion or osmotic
systems, for example, as described in “Remington—~The Science and Practice of
Pharmacy”, 20‘“. Ed., Lippincott Williams & Wilkins, Baltimore, Md., 2000). A diffusion
system typically consists of one of two types of devices, reservoir and matrix, which are
2014/000726
wellknown' and described in die art. The matrix devices are generally prepared by
compressing the drug with a slowly dissolving polymer carrier into a tablet form.
] An immediate release portion can be added to the extended release system by
means of either applying an ate release layer on top of the extended release core;
using coating or compression processes or in a le unit system such as a capsule
containing extended and immediate release beads.
Delayed release dosage formulations are created by coating a solid dosage form
with a film of a polymer which is insoluble in the acid environment of the h, but
soluble in the neutral environment of small intestines; The delayed release dosage units
can be prepared, for example, by coating a drug or a drug-containing composition with a
selected g material. The drug-containing composition may be a tablet for
incorporation into a capsule, a tablet for use as an inner core in a “coated core” dosage
fOrm, or a plurality of drug-containing beads, particles or granules, for incorporation into
either a tablet or capsule.
A pulsed release dosage form is one that mimics a multiple dosing profile
without repeated dosing and typically allows at least a twofold reduction in dosing
frequency as compared to the drug presented as a tional dosage form (e.g., as a
on or prompt drugéreleasing, conventional solid dosage form). A pulsed release
profile is characterized by a time period of no release (lag time) or reduced release
’followed by rapid drug release.
Each dosage form contains a therapeutically effective amount of active agent. In
one ment of dosage forms that mimic a twice daily dosing profile, approximately
wt. % to 70 wt. %, preferably 40 wt. % to 60 wt. %, of the total amount of active agent
in the dosage form is released in the initial pulse, and, correspondingly approximately 70
wt. % to 3.0 wt. %, preferably 60 wt. % to 40 wt. %,'of the total amount of active agent in
the dosage form is released in the second pulse. For dosage forms mimicking the twice
daily dosing profile, the second pulse is preferably released imately 3 hours to less
than 14 hours, and more preferably approximately 5 hours to 12 hours, following-
administration.
‘ Another dosage form contains a compressed tablet or a capsule having a drug-
containing immediate release dosage unit, a delayed release dosage unit and an optional
second delayed release dosage unit. In this dosage form, the ate release dosage
unit contains a plurality of beads, granules particles that e drug substantially
immediately following oral administration to provide an initial dose. The delayed release
dosage unit contains a plurality of coated beads or granules, which release drug
approximately 3 hours to 14 hours following oral administration to provide a second
dose.
For purposes of transdermal (e.g., topical) administration, dilute sterile, aqueous
or partially aqueous solutions (usually in about 0.1% to 5% tration), ise
similar to the above parenteral ons, may be prepared.
s of ing various pharmaceutical compositions with a certain
amount of one or more compounds of a I and formula II or other active agents are
known, or will be apparent in light of this disclosure, to those skilled in this art. For
examples of methods of preparing pharmaceutical compositiOns, see Remington’s
Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 19th Edition (1995).
In addition, in certain embodiments, subject itions of the present
application. maybe lyophilized or subjected to another appropriate drying technique such
as spray drying. The subject compositions may be administered once, or may be divided
into a number of smaller doses to be administered at varying intervals of time, depending ~
in part on the release rate of the compositions and the d dosage.
Formulations useful in the methods provided herein include those suitablefor
oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or
parenteral administration. The formulations may conveniently be presented in unit
dosage form and may be ed by any methods well known in the art of pharmacy.
The amount of a subject composition which may be combined with a r material to
produce a single dose may vary ing upon the subject being treated, and the
particular mode of administration.
Methods of preparing these formulations or compositions include the step of
bringing into association subject itions with the r and, optionally, one or
more accessory ingredients. In general, the formulations are prepared by unifome and
tely bringing into association a subject composition with liquid rs, or finely
divided solid rs, or both, and then, if necessary, shaping the product.
The. compounds of formula I and formula II described herein may be
administered in inhalant or aerosol formulations. The inhalant or aerosol ations
may se one or more agents, such as adjuvants, diagnostic agents, g agents,
or therapeutic agents useful in inhalation therapy. The final aerosol formulation may for
example contain 0.005-90%'w/w, for instance COOS—50%, 0.005—5% w/w, or 0.01-1.0%
w/w, of medicament relative to the total weight of the formulation.
In solid dosage forms for oral administration (capsules, tablets, pills, dragees,
powders, granules and the like), the subject composition is mixed with one or more
pharmaceutically acceptable carriers and/or any of the following: (1) fillers or extenders,
such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such
as, for example, carboxymethylcellulose, ‘alginates, gelatin, polyvinyl pyrrolidone,
sucrose and/or acacia; (3) humectants, such as ol; (4) disintegrating agents, such as
agar-agar, calcium ate, potato or tapioca starch, alginic acid, certain silicates, and
sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption
accelerators, such as quatemary‘ammonium compounds; (7) wetting agents, such as, for
example, acetyl l and glycerol monostearate; (8) absorbents, such as kaolin and
bentonite clay; (9) ants, such a talc, calcium stearate, magnesium te, solid
polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring
. In the case of capsules, tablets and pills, the pharmaceutical compositions may
' also se buffering agents. Solid compositions of a similar type may also be
employed as fillers in sofi and hard-filled gelatin capsules using lactose or milk_ sugars, as
well as high molecular weight polyethylene glycols and the, like.
[Liquid dosage forms for oral administration include pharmaceutically acceptable
emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In on to the
subject compositions, the liquid dosage forms may n inertdiluents ly used
in the art, such as, for example, water or other solvents, solubilizing agents and
emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl e,
benzyl alcohol, benzyl benzoate, propylene glycol, 01,3-butylene glycol, oils (in particular,
- cottonSeed, corn, peanut, sunflower, soybean, olive, castor, and sesame oils), glycerol,
tetrahydrofiiryl alcohol, hylene glycols and fatty acid esters of sorbitan, and
' mixtures thereof.
sions, in addition to the subject compositions, may contain suspending
agents such as, for example, ethoxylatedisostearyl alcohols, polyoxyethylene sorbitol,
and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-
agar and tragacanth, and mixtures thereof.’
Formulations for rectal or vaginal stration may be presented as a
suppository, which may be prepared by mixing a subject composition with one or more
suitable non—irritating carriers comprising, for example, cocoa butter, polyethylene
glycol, a itory wax, or a salicylate, and which is solid at room temperature, but
liquid at body temperature and, therefore, will melt in the appropriate body cavity and
e the encapsulated compound(s) and composition(s). Formulations which are
suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes,
foams, or spray formulations containing such'carriers as are known in the art to be
appropriate.
Dosage forms for transdermal administration include powders, sprays,
ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. ’ A subject
composition may be mixed under sterile conditions with a pharmaceutically able
carrier, and with any preservatives, buffers, or prOpellants that may be required. For
transdermal administration, the complexes may include lipophilic and hydrophilic groups
to achieve the desired water solubility and transport properties.
The ointments, pastes, creams and gels may contain, in addition to subject
compositions, other carriers, such as animal and vegetable fats, oils, waxes, paraffins,
starch, tragacanth, cellulose derivatives, polyethylene glycols, .silicones, bentonites,
silicic acid, talc and zinc oxide, or mixtures thereof. Powders and sprays may contain, in
addition to a subject composition, ents such as e, talc, silicic acid, um
ide, calcium silicates and ide powder, or mixtures of such nces.
Sprays may additionally contain customary propellants, such as
chlorofluorohydrocarbons and le tituted hydrocarbons, such as butane and
propane.
Methods of delivering a composition or compositions via a transderrnal patch are
known in the art. Exemplary s and methods of patch delivery are described in US
Patent Nos. 6,974,588, 6,564,093, 6,312,716, 6,440,454, 6,267,983, 6,239,180, and
6,103,275.
In r embodiment, a transdermal patch may comprise: a substrate sheet
comprising a ite film formed of a resin composition comprising 100 parts by
weight of a polyvinyl chloride-polyurethane composite and 2-10 parts by weight of a ,
styrene-ethylene-buty1ene-styrene copolymer, a first adhesive layer on the one side of the
composite film, and a polyalkylene terephthalate film adhered to the one side of the
composite film by means of the first adhesive layer, a primer layer which comprises a
saturated polyester resin and is formed on the surface of the polyalkylene terephthalate
film; and a second adhesive layer sing a styrene-diene-styrene block eopolymer
containing a pharmaceutical agent layered on the primer layer. A method, for the
manufacture of the above~mentioned substrate sheet ses preparing the above resin
composition molding the resin composition into a composite film by a calendar process,
and then adhering a polyalkylene terephthalate film on one side of the composite film by
means of an adhesive layer thereby forming the substrate sheet, and forming a primer
layer comprising a ted polyester resin on the outer surface of the polyalkylene
terephthalate film.
Another type of patch comprises incorporating the drug directly in a
pharmaceutically acceptable adhesive and laminating the drug-containing adhesive onto a
le g member, e.g. a polyester backing membrane. The drug should be t
at a concentration which will not affect the adhesive properties, and at the same time
deliver the required clinical dose.
Transdermal s may be passive or active. Passive transdermal drug
delivery systems currently available, such as the nicotine, estrogen and nitroglycerine
patches, deliver small-molecule drugs. Many of the newly developed proteins and peptide
drugs are too large to be delivered through passive transderrnal patches and may be
red using technology such as electrical assist (iontophoresis) for large-molecule
drugs.
, Iontophoresis is a technique ed for ing the flux of ionized
substances, through membranes by application of electric current. One example of an
horetic membrane is given in US. Pat. No. 5,080,646 to Theeuwes. The principal
mechanisms by which iontophoresis enhances molecular trémsport across the skin are (a)
repelling a charged ion from an electrode of the same charge, (b) electroosmosis, the
convective nt of solvent that occurs h, a charged pore in se the
preferential passage of counter-ions when an electric field is applied or (c) increase skin
permeability due to application of electrical current.
In some cases, it may be desirable to ster in the form of a kit, it may
comprise a container for containing the {separate compositions such as a divided bottle or
a divided foil packet. Typically the kit comprises directions for the administration of the
separate components. The kit form is particularly advantageous when the separate
components are preferably administered in different dosage forms (e.g., oral and
parenteral), are administered at different dosage intervals, or when titration of the
individual components ofthe combination is desired by the prescribing physician.
An example of such a kit is a so-called blister pack. Blister packs are well
known in the ing industry and are widely used for the ing of
‘ pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally
2014/000726
consist of a sheet ‘of relatively stiff al covered with a foil of a plastic material that
may be arent.
Methods and compositions for the treatment of multiple sclerosis. Among other
things, herein is provided a method of treatingmultiple sclerosis, comprising
administering to a patient in need thereof a therapeutically eflective amount of compound
ofFormula I:
Formula I
Wherein,
Rl , R3 each independently represents fCH3C0-, acetyl, D, H, CD3CO-,
O O
Trio 0371/. Eli; §\J\/2‘L
R2 , R4 each ndently represents H, D,
WO 51420
WO 51420
WO 51420
“a; 0
How dit \
~ ,HZN OH
,JKMJIelf O
\ e,
_ AIM/N,
7 3
NH O
a is independently 2,3 or 7;
each h is independently 3, 5 or 6;
e is independently 1, 2 or 6;
c and d are. each independently H, D, -OH, —OD, C1-C6-alkyl, .NH2 or £00m.
Accordingly, in another aspect the methods and compositions for the treatment of
multiple sclerosis. Among other things, herein is provided a method of ng multiple
WO 51420
sclerosis, comprising administering to a patient in need thereof a therapeutically effective
amount of compound of Formula II:
Formula II
Wherein
Rl R3 each independently represents H, D,
NH2 NH2
fWK/‘KW‘LLE—o—E
£52”N\/\’/\/N5\ xx”k
/\O/\/“\§\, E-JK/E,
“ax/NA;swat3
gnws/Vnyf
or ENE/waif:
R2 R4 each independently represents D, CH3CO, CD3CO,
WO 51420
WO 51420
O 0
,/ 9v“\ 0
HO 0
\ , H
' H2N
NH2 - OH
0271/
HO OH O
9 ,
WO 51420
16‘ OH
' OH
2014/000726
a is independently 2,3 or 7;
each b is independently 3, 5 or 6;
e is independently 1, 2 or 6;
c and d are each independently H, D, -OH, -OD, C1-C5-alkyl, -NH2 or —COCH3.
METHODS OF MAKING
Examples of tic pathways fiseful for making compounds of formula II are
Set forth in example below and generalized in scheme 1:
Scheme-1:
‘l’ 0 V
0 DCC.DMAP, /
OH L- . 5N HCI,
0 HOJK/Z\COZMe—————> 07W COzMe.
1 DCM’ rt, 2“
c H o )V Dioxane, rt, 1-2h
C5H1203 "
Mol M1010 , 0“”.160“ ,
MoI.WL:132,16 ' " - Step-1 »
_ Mol.Wt..244.2ft Step-2
o a
. OH
Ho/fiflo COzMe —
A ,
HO 4
+ .
, "0'5on . DCM,rt,2h
C H O -
. 20 so 2
'Mol. \th.1:220§l.18 Mol. Wt.: 302.45 Step-3
MOWOWCOZMe_ _
0'
. DCC.DMAP,
- O7 _. _________)
Mol. Wt.: 488.61 ~ DCM, rt, 2h
0 Step-4
Mol. M: 130.10
CsaH4401o
Mol. Wt.: 600.70
Step-l: Synthesis ofcompound 3:
I O DCC, DMAP,
O O/Y\OJJ\/\002Me
OH .
o -H0 COM6 DCM, rt. 2h )VO 3
1 2
C6H1203 C5HBO4 . C11H1606
' MOI. \Nt.: 132.16 MOI. VVt.'. 130.10 MOI. VVt.2 244.24
To a solution of INT-1 (30g, 0.22 mol), INT-2 (38g, 0.29 mol), DMAP (26g,
0.22 mol) in Dichloromethane (200 ml) was added drop wise the solution of DCC (50g,
0.24 mol) in Dichloromethane (100 ml) under nitrogen atmosphere at 25°C. After the
on, reaction mixture was d for 2—3 h at 25°C. The Progress of reaction was
monitored by TLC. Reaction mixture was filtered to remove DCU byproduct and bed
washed with Dichloromethane (2 x 20ml). The collected filtrate was washed with DM
water (1 x 150 ml), 5% hydrochloric acid solution (1 x 50 ml), sat. Sodium onate
solution (1 x 100 ml), washed with 10% brine solution (1 x 50 ml). The ted organic
layer was dried (anh. NaZSO4) filtered and distilled off under reduced pressure at 40-
45°C. The crude was dissolved in hexane (600 ml) filtered immediately to remove
insoluble impurities (DCU). Collected filtrate was concentrated under reduced pressure to
m volume (~50-100 ml). Filtered product and bed washed with, hexane (2 x 50
ml), air dried product at 35-40°C to afford INT- 3 (40g, 74%) as off white powder.
Stepe2: Synthesis ofcompound 4:
M O
o/TO 5N HCI,
)T 3 COzMe_________> Ho/WAOMCOWIG
Dioxane, rt, 1-2h HO 4
C11 H1606 CsH1206
Mol. Wt.§244.24 MOI. \Nt.: 204.18
To a solution of INT-3 (20g, 0.08 mol) in Dioxane (100 ml) was added drop wise
5N Hydrochloric acid (100 ml) at 25°C. The reaction mixture was d for 1h at 25°C
and Progress of reaction was monitored by TLC. After starting al was consumed
completely, the reaction mixture was neutralized by addition of solid sodium carbonate
until Ph was basic (~Ph 8) and crude mass was filtered off to remove inorganic materials.
The filtrate was concentrated under reduced pressure to remove dioxane and aqueous
layer was extracted with Ethyl acetate (2 x 100 ml) and combined organic extracts were
dried (NaZSO4), filtered and‘concentrated under d pressure at 40-45°C. The crude
residue was stirred in di-isopropyl ether (100 ml) for 4-6h and the suspension was
d. Isolated product was air dried at 40-50°C to afford TNT-4 (10g, 60%) as off
white solid.
Step-3: Synthesis of compound 5:
bMOHDCC DMAP Ho/YO COzMe *“
— 7‘ ——-—'———’>
HO 4 + DCM, n, 2h
0 H 0 C EfiAo20 so 2
M01. €Vt.1:22064.18 Mol, Wt: 302.45 Step-3
WCOZW—' _
O
CzaH4007
MOI. Wt: 488.61
To a solution of TNT-4 (10 g, 0.04 mol), EPA (16.2 g, 0.05 mol), DMAP (2.9g,
0.02 mol) in Dichloromethane (400 ml) was added the solution of DCC (109 g, 0.05
‘mol) in Dichloromethane (100 m1) under nitrogen atmosphere at 25°C. After the addition,
reaction mixture was d for 1-2 h at 25°C. The Progress of reaction was monitored by
TLC. Reaction mixture was filtered to remove DCU byproduct and bed washed with
Dichloromethane (2 x 25 ml). The collected filtrate was washed with DM water (1 x 150
m1), 5% hloric acid on (1 x 50 ml), sat. Sodium bicarbonate solution (1 x 100
ml), washed with 10% brine solution (1 x 50 ml). The organic layer was dried (Na2804),
filtered and solvent was distilled off at reduced pressure at 40-45°C. The crude was
purified by passing over silica gel column (60-120 mesh) by eluting with 15-20% Ethyl
acetate: Hexane to afford INT-5 (11g, 46%).
] Step-4: Synthesis of compound 6:
Ofl/OWI/Vcozwle
O V O
Cst4007
Mol. Wt.: 488.61
DCC, DMAP,
HOMCOZMe V DCM. rt, 2h
2 ' Step-4
. C5H504
MOI. Wt: 130.10
o COzMe
C331444010 0
MOI. VW; 600.70
] To a solution of INT-5 (11 g, 24mmol), MMF (3.8 g, 29 mmol), DMAP (2.9 g,
24 mmol) in Dichloromethane (80 ml) was added the sclution of DCC (4.9 g, 24 mmol)
in Dichloromethane (30 ml) under nitrogen atmosphere at 25°C. After the addition,
reaction mixture was stirred for 1-2 h at 25°C. The Progress of on was monitored by
TLC. Reaction mixture was filtered to remove DCU byproduct and bed washed with
Dichloromethane (2 x 15 ml). The collected filtrate was washed with DM Water (1 x 100
ml), 5% hydrochloric acid solution (1 x 25 ml), sat. Sodium bicarbonate solution (1 x 25
ml), washed with 10% brine solution (1 x 25 ml). The organic layer was dried (NaZSO4),
filtered and t'was distilled ofi‘ at reduced pressure at 40-45°C. The crude was
purified by passing over silica gel column (60-120 mesh) by eluting with 10-13% Ethyl
acetate: Hexane to afford final compound 6 (10g, 73%).
WO 51420
The term “sample” refers to a sample of a body fluid, to a sample of separated
cells or to a sample from a tissue or an organ. Samples of body fluids can be obtained by
well—knowntechniques and include, preferably, s of blood, plasma, serum, or
urine, more preferably, samples of blood, plasma or serum. Tissue or organ samples may
be obtained from any tissue or organ- by, e.g., biopsy. ted cells may be obtained
from the body fluids or the tissues or organs by separating techniques such as
fugation or cell sorting.
EQUIVALENTS
The present di5closure provides among other things compositions and. methods
for treating multiple sclerosis and their complications. While specific embodiments of
the subject disclosure have been discussed, the above speCification‘is illustrative and not
restrictive. Many variations of the systems and methods herein will become apparent to
those skilled in the art upon review of this specification. The full scope of the claimed
s and s should be detemrined by reference to the claims, along with their
full scope of lents, and the specification, alongwith such variations.
INCORPORATION BY REFERENCE ' ‘
All publications and patents mentioned herein, .including those items listed
above, are hereby incorporated by reference in their entirety as if each individual
publication or patent was ispecifically and individually indicated to be incorporated by
reference. In case of conflict, the present application, including any ions herein,
will control.
Claims (7)
1. A compound of Formula II: Formula II or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, or stereoisomer thereof; wherein R1, R3 are each independently null : R2 is ; and R4 represents 17897448_1 ters) P109613.NZ
2. A nd of claim 1, wherein the compound has the chemical structure of:
3. A compound of claim 1, wherein the compound has the chemical structure of:
4. A pharmaceutical composition comprising a compound of any of claims 1 to 3 and a pharmaceutically acceptable r.
5. The pharmaceutical ition of claim 4, which is formulated for oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.
6. The pharmaceutical composition of claim 4, which is formulated for use in the treatment of neurodegenerative es, multiple sis, psoriasis and inflammatory diseases.
7. Use of a compound of any of claims 1 to 3 for the manufacture of a medicament for the treatment of neurodegenerative diseases, le sclerosis, psoriasis and inflammatory diseases. 17897448_1 (GHMatters) P109613.NZ
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN4873/CHE/2014 | 2014-09-29 | ||
IN4873CH2014 | 2014-09-29 | ||
PCT/IN2014/000726 WO2016051420A1 (en) | 2014-09-29 | 2014-11-20 | Compositions and methods for the treatment of multiple sclerosis |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ731396A NZ731396A (en) | 2021-08-27 |
NZ731396B2 true NZ731396B2 (en) | 2021-11-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014407862B2 (en) | Compositions and methods for the treatment of multiple sclerosis | |
US9434704B2 (en) | Compositions and methods for the treatment of neurological degenerative disorders | |
US20150133533A1 (en) | Compositions and methods for the treatment of cough | |
WO2014087367A2 (en) | Compositions and methods for the treatment of neurological diseases and its associated complications | |
US9580383B2 (en) | Compositions and methods for the treatment of multiple sclerosis | |
US20150210667A1 (en) | Compositions and methods for the treatment of autonomic and other neurological disorders | |
WO2017033119A1 (en) | Compositions and methods for the treatment of liver metabolic diseases | |
AU2013257706A1 (en) | Compositions and methods for the treatment of neurological disorders | |
WO2014195850A2 (en) | Compositions and methods for the treatment of neurologic diseases and neurological disorders | |
CA2873084A1 (en) | Compositions and methods for the treatment of diabetes | |
US9242939B2 (en) | Compositions and methods for the treatment of respiratory disorders | |
NZ731396B2 (en) | Compositions and methods for the treatment of multiple sclerosis | |
WO2014068459A2 (en) | Compositions and methods for the treatment of pain and neurological diseases | |
WO2015028957A2 (en) | Compounds and methods for the treatment of respiratory diseases | |
WO2015028956A1 (en) | Compositions and methods for the treatment of fatty acid oxidation disorders | |
US9187427B2 (en) | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases | |
WO2014174421A2 (en) | Compositions and methods for the treatment of respiratory diseases | |
US9399634B2 (en) | Compositions and methods for the treatment of depression | |
US20150141384A1 (en) | Compositions and methods for the treatment of neurological degenerative disorders | |
WO2015028928A2 (en) | Compositions and methods for the treatment of inflammation and arthritis | |
WO2014060941A2 (en) | Compositions and methods of neuroprotective agents for the treatment of neurological and neurodegenerative diseases | |
WO2015008205A2 (en) | Compositions and methods for the treatment of respiratory diseases | |
WO2016046669A2 (en) | Compositions and methods for the treatment of depression and neurological diseases | |
WO2015001499A2 (en) | Compositions and methods for the treatment of irritable bowel syndrome and the associated abdominal cramping | |
WO2015028927A1 (en) | Compositions and methods for the treatment of metabolic diseases |